$Septerna (SEPN.US)$
It is said that this company is heavily oversubscribed, widely bullish on Wall Street, with a high probability of a premium of +2 or more at the opening, so stay tuned!
The only platform available for subscription is Futu, Futu.Account opening link https://a.webull.com/Nwch25cS8sLdNiNjGW
The biotechnology company in the first quarter expanded its IPO size by 57% to 15.28 million shares,It is said that the pricing per share is at the high end of 15-17, or +1 to 18.00 US dollars.
JP Morgan, TD Cowen, Cantor, and Wells Fargo Securities are acting as joint bookrunners.
Major shareholders include affiliated entities of Third Rock Ventures (pre-IPO ownership 33.5%, post-IPO ownership 21.1%); RA Capital affiliated entities (pre-IPO ownership 10.9%, post-IPO ownership 6.8%); Samsara BioCapital, LP affiliated entities (pre-IPO ownership 8.5%, post-IPO ownership 5.4%); and affiliates of Goldman Sachs (pre-IPO ownership 5.4%, post-IPO ownership 3.4%).
Financial overview: net loss of 46.2 million US dollars, revenue of approximately 0.84 million US dollars (840,00...

$Bowhead Specialty (BOW.US)$
Long-term holding for 5 years, target price 300+